Evidence map›Paper›PMID 31211399›Full record

ArticleRheumatology (Oxford, England)2019

Comparison of disease activity measures in early psoriatic arthritis in usual care.

Kim Wervers, Jolanda J Luime, Ilja Tchetverikov, Andreas H Gerards, Marc R Kok, Cathelijne W Y Appels, Wiebo L van der Graaff, Johannes H L M van Groenendael, Lindy-Anne Korswagen, Josien J Veris-van Dieren and 3 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Measuring Outcomes in Psoriatic Arthritis.Arthritis care & research · 2020
    Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kim WerversDepartment of Rheumatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Jolanda J LuimeDepartment of Rheumatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Ilja TchetverikovDepartment of Rheumatology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Andreas H GerardsDepartment of Rheumatology, Vlietland Hospital, Schiedam, The Netherlands.
Marc R KokDepartment of Rheumatology, Maasstad Hospital, Rotterdam, The Netherlands.
Cathelijne W Y AppelsDepartment of Rheumatology, Amphia Hospital, Breda, The Netherlands.
Wiebo L van der GraaffDepartment of Rheumatology, Rivas Hospital, Gorinchem, The Netherlands.
Johannes H L M van GroenendaelDepartment of Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, The Netherlands.
Lindy-Anne KorswagenDepartment of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, The Netherlands.
Josien J Veris-van DierenDepartment of Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, The Netherlands.
Johanna M W HazesDepartment of Rheumatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Marijn VisDepartment of Rheumatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
for CICERO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo compare responsiveness and longitudinal validity of Disease Activity Score 28 (DAS28), Disease Activity index for PSoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic ArthritiS Disease Activity Score (PASDAS), GRAppa Composite scorE (GRACE) and Minimal Disease Activity (MDA) in usual care PsA patients, within 1 year after diagnosis.

methodsData collected in the Dutch southwest early PsA cohort (DEPAR) were used. Responsiveness was assessed using effect size (ES), standardized response mean (SRM), and discrimination between different general health states. Longitudinal validity was tested using mixed models with outcomes health-related quality of life (HRQOL), productivity and disability.

resultsResponsiveness was highest for PASDAS, with ES 1.00 and SRM 0.95, lowest for DAPSA, with ES 0.73 and SRM 0.71, and in between for DAS28, CPDAI and GRACE. Differences in general health were best discriminated with PASDAS and GRACE. Patients reporting stable or worsening general health could not be distinguished by DAS28 or CPDAI. Discrimination was better using DAPSA, but worse than when using PASDAS and GRACE. Longitudinal evolvement of HRQOL and productivity had the highest association with low disease activity according to GRACE, followed by PASDAS, MDA, DAPSA, DAS28, with the lowest association for CPDAI.

conclusionPASDAS and GRACE were superior with respect to responsiveness, and together with MDA best related to longitudinal evolvement of HRQOL, productivity and disability. Responsiveness and longitudinal validity of most outcomes were inferior for DAS28, DAPSA and CPDAI. As alternatives to the continuous measure DAPSA, use of PASDAS or GRACE should be considered.

Indexed as

Health StatusQuality of LifeArthritis, PsoriaticFemaleFollow-Up StudiesHumansMaleMiddle AgedOutcome Assessment, Health CareReproducibility of ResultsRetrospective StudiesSeverity of Illness IndexSurveys and QuestionnairesTime Factorsdisease activitylongitudinal validitypsoriatic arthritisresponsiveness

Identifiers

PMID31211399
PMCPMC7032073

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.